Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
NCT00880711 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57
Last updated 2011-11-30
Summary
The purpose is to collect real life data on the use of fulvestrant in normal clinical practice in Austria and document the clinical benefit of fulvestrant treatment.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Guenther Steger, Univ Prof. Dr. · Medical University of Vienna
Eligibility
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-04-30
- Primary Completion
- 2010-09-30
- Completion
- 2010-12-31
Countries
- Austria
Study Locations
More Related Trials
-
Fulvestrant in Metastatic Breast Cancer
NCT03591549 ·Status: UNKNOWN ·Phase: PHASE4
-
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
NCT01942135 ·Status: COMPLETED ·Phase: PHASE3
-
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
NCT02447328 ·Status: COMPLETED ·Phase: PHASE4
-
SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex® After Aromatase Inhibitor Failure in Advanced Breast Cancer
NCT00272740 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI
NCT01797120 ·Status: COMPLETED ·Phase: PHASE2
-
ICI 182780 in Treating Women With Metastatic Breast Cancer
NCT00012025 ·Status: COMPLETED ·Phase: PHASE2
-
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant
NCT03447132 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
NCT00234403 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
NCT03202862 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
NCT03377101 ·Status: WITHDRAWN ·Phase: PHASE2
-
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT03633331 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
NCT00570921 ·Status: COMPLETED ·Phase: PHASE2
-
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
NCT00752986 ·Status: TERMINATED ·Phase: PHASE2
-
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
NCT04920708 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
NCT02530411 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
NCT02690480 ·Status: UNKNOWN ·Phase: PHASE2
-
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
NCT00010153 ·Status: TERMINATED ·Phase: PHASE3
-
A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)
NCT00927511 ·Status: UNKNOWN ·Phase: PHASE2
-
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
NCT00138125 ·Status: TERMINATED ·Phase: PHASE2
-
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
NCT02540330 ·Status: TERMINATED ·Phase: PHASE2
-
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
NCT01320111 ·Status: COMPLETED ·Phase: PHASE2
-
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
NCT00082810 ·Status: COMPLETED ·Phase: PHASE2
-
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05438810 ·Status: UNKNOWN ·Phase: PHASE3
-
Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
NCT02789332 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
NCT02340221 ·Status: TERMINATED ·Phase: PHASE3